retatrutide doses clinical trial Reta data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP retatrutide dosing phase 2 trial

The container was small enough that I threw it in my personal item for travel, and could stow it in my purse for dinners out

Endocrinology 143 : 13531361 Cummings DE et al

Why the Injection Site Matters You might wonder, If the medicine is going under my skin, why cant I just pick any spot? Here are three big reasons site choiceand rotationreally counts: 1

Nausea: the most common side effect Nausea affected approximately 27% of retatrutide users in clinical trials across all doses

GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study

All that remains to be seen, and an absolute benefit of 1.5 per 100 people treated is certainly nothing to write home about